News
EssilorLuxottica Aktie: Expansion geht weiter
Der französisch-italienische Brillenkonzern setzt seinen Kaufrausch fort. Am Freitag gab das Unternehmen die Übernahme…
Der Beitrag EssilorLuxottica Aktie: Expansion geht weiter erschien zuerst auf
EssilorLuxottica Aktie: Innovationspreis erhalten!
Der französisch-italienische Brillengigant überrascht mit spektakulären Zahlen: 6,87 Milliarden Euro Umsatz im dritten Quartal…
Der Beitrag EssilorLuxottica Aktie: Innovationspreis erhalten!
EssilorLuxottica Aktie: Großangriff auf Nikon
Der Brillengigant EssilorLuxottica plant offenbar eine deutliche Ausweitung seiner Beteiligung am japanischen Kamera- und…
Der Beitrag EssilorLuxottica Aktie: Großangriff auf Nikon erschien zuerst
EssilorLuxottica Stock: Smart Eyewear Drives Record Growth
EssilorLuxottica has posted impressive half-year results, with currency-adjusted revenue increasing by 7.3% to €14.02 billion, significantly exceeding analyst expectations. The standout performer
Sanofi Stock: $9.1 Billion Blueprint Deal Sparks Debate
The French pharmaceutical giant Sanofi has announced plans to acquire US-based Blueprint Medicines for $9.1 billion, marking a strategic push into the specialized immunology market. The ambitious
Sanofi Stock: Setback in Lung Drug Trial Hits Shares
The French pharmaceutical giant Sanofi faced a significant blow as its lung medication candidate Itepekimab delivered mixed Phase III trial results. While one of the critical studies showed the drug
Sanofi Stock: $600M Alzheimer Drug Acquisition Bet
Sanofi has made a strategic move to strengthen its neurology portfolio by acquiring Vigil Neuroscience for up to $600 million. The French pharmaceutical giant will pay $470 million ($8 per share)
Sanofi Stock: FDA Approves Breakthrough Hemophilia Treatment
Sanofi has received FDA approval for Qfitlia, its innovative hemophilia therapy that represents the first antithrombin-lowering treatment for hemophilia A or B patients with or without inhibitors
EssilorLuxottica Stock: Profit Margins Soar, Smart Eyewear Drives Growth
EssilorLuxottica, the global leader in eyewear and optical products, has demonstrated remarkable financial performance in its latest fiscal year. The Franco-Italian eyewear giant reported a 4.4%
Sanofi Stock: L'Oréal Sells $3.2B Stake in Major Deal
L'Oréal, the French cosmetics giant, has announced a significant restructuring of its investment in pharmaceutical company Sanofi through an off-market block trade. The transaction involves the sale
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: Information on Document Availability
Half-year results 2025 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Incoming Sartorius CEO Michael Grosse to become Chairman of the Board of Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech expands manufacturing and R&D capacities for innovative bioprocess solutions in France
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech publishes unaudited first quarter results for 2025